tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Foghorn Therapeutics Reports Q2 2025 Financial Update

Story Highlights
Foghorn Therapeutics Reports Q2 2025 Financial Update

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

An announcement from Foghorn Therapeutics ( (FHTX) ) is now available.

On August 5, 2025, Foghorn Therapeutics provided a financial and corporate update for the second quarter of 2025, highlighting significant progress in its oncology pipeline. The company is advancing its FHD-909 Phase 1 trial for SMARCA4 mutated cancers, with promising preclinical results in combination with pembrolizumab and KRAS inhibitors. Foghorn’s selective degrader programs, including CBP, EP300, and ARID1B, are progressing well, with updates expected in late 2025. The company maintains a strong financial position with a cash runway extending into 2028, positioning it well for future developments.

The most recent analyst rating on (FHTX) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Foghorn Therapeutics stock, see the FHTX Stock Forecast page.

Spark’s Take on FHTX Stock

According to Spark, TipRanks’ AI Analyst, FHTX is a Neutral.

Foghorn Therapeutics’ stock score is primarily impacted by its challenging financial performance, characterized by negative equity and ongoing losses. Technical indicators suggest a potential for recovery with oversold signals. Positive corporate events, including progress in clinical trials and strong cash position, offer some optimism. However, valuation remains a concern with negative earnings.

To see Spark’s full report on FHTX stock, click here.

More about Foghorn Therapeutics

Foghorn Therapeutics Inc. is a clinical-stage biotechnology company focused on developing a new class of medicines aimed at correcting abnormal gene expression, primarily targeting oncology. The company utilizes its Gene Traffic Control® Platform to address a wide spectrum of diseases, with a strong emphasis on cancer treatment.

Average Trading Volume: 132,898

Technical Sentiment Signal: Sell

Current Market Cap: $278.1M

For a thorough assessment of FHTX stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1